Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by JMark80on Jun 11, 2020 12:14pm
60 Views
Post# 31138924

RE:RE:funny when someone rises concerns re eg funding which

RE:RE:funny when someone rises concerns re eg funding whichThey haven't already "gotten" $84mm.

"BARDA awarded Salzman Group a USD $84.9M contract to develop R-107 as a treatment for CILI"
 
"$15M has been funded and spent – $70M in follow-on funding will be released on completion of milestones"

"From the $70M of revenues, Kalytera will recognize $4.2M of net operating profit".

"Because Phase 2 and 3 studies in humans will not be required, the timeline for FDA approval is expected to be relatively brief, about 2.5 years."

How many years will COVID take?

"Potential sales of CILI product to BARDA"

We don't know the terms of the contract. However, since BARDA is paying $84.9mm for development for CILI, how much, if anything, will Kalytera make on sales?

If they don't receive BARDA for COVID, company is done.
<< Previous
Bullboard Posts
Next >>